RIEMSER Pharma
RIEMSER Pharma is a specialty pharmaceutical company operating in rare diseases and CDMO services; the dominant data set describes a Spain-based international pharma with rare-disease products and contract manufacturing across Europe, Asia, and America.
- Company typePrivate
- Founded1929
- HeadquartersGreifswald, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What RIEMSER Pharma does
RIEMSER Pharma GmbH is identified in the firmographic data as a specialty pharmaceutical company headquartered in Greifswald, Germany, founded in 1990 with 11-50 employees. The aggregated source material, however, is dominated by a separate but possibly related entity — an international specialty pharmaceutical company headquartered in Spain, founded approximately 1929, with 744 million euros in FY2024 net sales (5% year-over-year growth) and subsidiaries across Europe, Asia, and America. The entity's core products include specialty pharmaceuticals for rare diseases with high unmet medical need, specifically Caprelsa (Vandetanib) for medullary thyroid carcinoma and a licensed treatment for severe primary IGF-1 deficiency. Beyond proprietary products, the company offers contract development and manufacturing services (CDMO) for small-molecule active pharmaceutical ingredients from preclinical through commercial scale, and operates B2B partnering arrangements for licensing and distribution.
The business model combines direct pharmaceutical product sales (specialty/rare disease) with B2B CDMO services and licensing partnerships. Geographic distribution flows through traditional pharmaceutical channels including wholesalers, pharmacies, and direct hospital sales, anchored by wholly-owned regional subsidiaries in Europe, Asia, and America. Customer-facing engagement is structured around patient, healthcare professional, and business partner segments, with marketing executed through corporate web, LinkedIn, Instagram, and a dedicated media/news center. The acquisition history includes Intrapharm Laboratories (2015), Keocyt (2014), Riemser Speciality Production (2008), and most recently Regis Technologies (2025) and Caprelsa (2025), supplemented by a 2025 licensing agreement for IGF-1 deficiency treatment — collectively indicating an M&A-driven international expansion strategy focused on rare-disease therapeutics and CDMO scale. Historical equity backing includes TVM Capital (2008) and Nord Holding (2005).
Note: The source data exhibits a significant identity conflict between the German RIEMSER Pharma entity (Greifswald, founded 1990, 11-50 employees) and the much larger Spanish-domiciled entity described in the majority of the structured content. The analytical content above reflects primarily the dominant data narrative; the RIEMSER-specific personnel (Beate Küter, COO Germany; Magdalena Poznanski, BD manager) and earlier acquisitions point to a distinct German operation whose full profile is not disclosed in the available material.
RIEMSER Pharma firmographics
Firmographics- Name
- RIEMSER Pharma
- Legal name
- ESTEVE
- Website
- https://riemser.de
- Company type
- Private
- Founded year
- 1929
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RIEMSER Pharma is a specialty pharmaceutical company operating in rare diseases and CDMO services; the dominant data set describes a Spain-based international pharma with rare-disease products and contract manufacturing across Europe, Asia, and America.
- Ownership category
- akta.pro rank
RIEMSER Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Pharmaceutical Distributors (HLAIAJAB)
Keywords
Where RIEMSER Pharma is headquartered
LocationHeadquarters
- HQ city
- Greifswald
- HQ country
- Germany
- HQ region
- Europe
Markets served
RIEMSER Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Distribution channels3 records
Marketing channels4 records
RIEMSER Pharma product offering
Product offeringCore offering
RIEMSER Pharma GmbH (formerly RIEMSER Arzneimittel AG) is an international specialty pharmaceutical company headquartered in Greifswald, Germany, focused on developing, marketing, and distributing specialty pharmaceutical products. The company also operates contract manufacturing (Auftragsfertigung) services and B2B partnering arrangements, and has grown through acquisitions of specialty pharma assets such as Intrapharm Laboratories, Keocyt, and Riemser Speciality Production.
Product overview
ESTEVE is an international pharmaceutical company offering a portfolio of pharmaceutical products across therapy areas, contract manufacturing services (Auftragsfertigung), and B2B partnering solutions. The company operates across multiple regions including Benelux, France, Germany, Italy, Portugal, Spain, and the UK, with subsidiaries in Asia and America. Core offerings include specialty pharmaceutical products like Caprelsa® (Vandetanib) for medullary thyroid carcinoma, an innovation pipeline, and contract development and manufacturing services for small-molecule pharmaceutical active ingredients.
Differentiator
Problem solved
Functional benefit
Products and services
- Specialty pharmaceutical product portfolio
Quantifiable outcome
- 5% net sales growth
Companies that use RIEMSER Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
RIEMSER Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
RIEMSER Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Regis TechnologiescoreEsteve acquired Regis Technologies to expand its presence and offerings in the United States. The acquisition enables Esteve to extend its contract development and manufacturing services for small molecule pharmaceutical active ingredients from preclinical through commercial manufacturing in the US market.
- Licensing Partner (IGF-1 Deficiency Treatment)coreEsteve signed a licensing agreement for a pharmaceutical product to treat severe primary deficiency of insulin-like growth factor-1 (primary IGF-1 deficiency). This agreement represents Esteve's strategic focus on highly specialized therapies for conditions with high unmet medical need.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
RIEMSER Pharma competitors and assessment
Company assessmentDirect peers
- Dermapharm Holding: German specialty pharmaceutical company focused on niche therapeutic areas including dermatology, allergies, and pain. Comparable as a German specialty pharma player with similar focused market approach and European distribution footprint.
- Faes Farma: Spanish specialty pharmaceutical company focused on prescription and OTC products across multiple therapeutic areas. Comparable as a Southern European specialty pharma with similar niche market approach and Iberian heritage similar to Estee.
- Almirall: Spanish specialty pharmaceutical company focused on dermatology and specialty conditions. Comparable as a Southern European specialty pharma player with similar market positioning to Estee/RIEMSER and similar portfolio-based approach.
- Orion Corporation: Finnish specialty pharmaceutical company with focus on neurology, critical care, and specialty therapeutics. Comparable as a European specialty pharma player with similar market positioning and diversified specialty portfolio approach.
- Recordati: Italian-headquartered European specialty pharmaceutical company with focus on rare diseases and specialty therapeutics. Comparable as a European specialty pharma player with similar positioning in niche therapeutic areas and international growth strategy.
- Merz Pharma: German specialty pharmaceutical company focused on aesthetics, neurology, and consumer care. Comparable as a German-headquartered specialty pharma player with private ownership structure and international distribution similar to RIEMSER's positioning.
- Neuraxpharm: European specialty pharmaceutical company focused on central nervous system (CNS) disorders. Comparable as a privately-held European specialty pharma player with similar focus on niche therapeutic areas and PE-backed history.
- Stada Arzneimittel: German specialty and generics pharmaceutical company headquartered in Bad Vilbel. Directly comparable as a German specialty pharma player with similar geographic focus on European markets and a portfolio-based business model targeting niche therapeutic areas.
Broad incumbents
- Hikma Pharmaceuticals: UK-headquartered specialty and generic pharmaceutical company with global presence across MENA, Europe, and North America. Comparable as a larger specialty pharma player with similar European base and broad international distribution.
- Ipsen: French specialty pharmaceutical company focused on oncology, neuroscience, and rare diseases. Comparable as a larger incumbent specialty pharma player with similar therapeutic focus areas and European base, though with significantly greater scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
RIEMSER Pharma social profiles
Digital presenceRIEMSER Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
RIEMSER Pharma leadership team
Management profileNumber of profiles
Profiles2 records
RIEMSER Pharma subsidiaries and ownership
Company hierarchySubsidiaries3 records
RIEMSER Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RIEMSER Pharma M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RIEMSER Pharma
What does RIEMSER Pharma do?
RIEMSER Pharma GmbH (formerly RIEMSER Arzneimittel AG) is an international specialty pharmaceutical company headquartered in Greifswald, Germany, focused on developing, marketing, and distributing specialty pharmaceutical products. The company also operates contract manufacturing (Auftragsfertigung) services and B2B partnering arrangements, and has grown through acquisitions of specialty pharma assets such as Intrapharm Laboratories, Keocyt, and Riemser Speciality Production.
Is RIEMSER Pharma a public or private company?
RIEMSER Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was RIEMSER Pharma founded?
RIEMSER Pharma was founded in 1929. It employs 11 to 50 people.
Where is RIEMSER Pharma based?
RIEMSER Pharma is headquartered in Greifswald, Germany, in the Europe region.
Who are RIEMSER Pharma's main competitors?
Direct peers on record are Dermapharm Holding, Faes Farma, Almirall, Orion Corporation, Recordati, Merz Pharma, Neuraxpharm and Stada Arzneimittel. Broad incumbents are Hikma Pharmaceuticals and Ipsen.
Does RIEMSER Pharma have an API?
No public API is recorded for RIEMSER Pharma.
What industry is RIEMSER Pharma in?
RIEMSER Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.